Form 4: Lilly Endowment sells 9,886 Eli Lilly shares

Lilly Endowment, a 10% owner of Eli Lilly (LLY), disclosed open-market sales totaling 9,886 shares at ~$1,031, retaining 92.87 million shares.

Summary

• A 10% owner, Lilly Endowment Inc., executed two open-market sales of Eli Lilly common stock on 11/17/2025 totaling 9,886 shares.
• Sales were reported at weighted average prices of $1,030.448 (7,789 shares; price range $1,030.00–$1,030.99) and $1,031.526 (2,097 shares; price range $1,031.00–$1,031.75).
• Post-transaction beneficial ownership stands at 92,872,191 shares, down from 92,882,077 shares pre-sale.
• The aggregate sale represents approximately 0.0106% of the Endowment’s pre-transaction holdings, a de minimis reduction.
• Transactions were coded “S” (open-market sale).
• Signatory: Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.; filing dated 11/18/2025.

Sentiment

Score: 5

Explanation: Neutral; the transaction is small relative to the holder’s stake and contains no operational or financial performance updates.

Positives

• Endowment retains a very large position: 92,872,191 shares after the trades.
• Sale size is immaterial relative to its holdings (~0.0106% of pre-sale position).
• Transparent disclosure of weighted average prices and price ranges, with an undertaking to provide detailed trade breakdowns upon request.

Negatives

• Insider sale by a 10% owner can be perceived negatively by some investors.
• Slight reduction of long-held strategic stake (9,886 shares sold).

Future Outlook

No guidance or forward-looking statements are included.

Management Comments

• Weighted average prices were disclosed; trades occurred across specified price ranges, and detailed breakdowns will be provided upon request.
• Signed by Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.

Industry Context

Insider transaction disclosures by large shareholders are routine. Small, incremental sales by long-term holders such as foundations or endowments are common and typically reflect portfolio management rather than shifts in company fundamentals.

Comparison to Industry Standards

• The sale represents ~0.0106% of the holder’s stake, a negligible proportion consistent with routine rebalancing by large institutional holders across mega-cap pharma peers.
• Relative to typical insider transactions among large-cap pharmaceutical companies (e.g., Johnson & Johnson, Pfizer, Merck), the absolute size and proportional impact of this sale are minimal and unlikely to affect control or governance.

Stakeholder Impact

• Shareholders: Minor insider selling may be viewed cautiously by some, but the immaterial size suggests no signal on fundamentals.
• Market liquidity: Slight increase in public float due to secondary market sales.
• Governance/control: No meaningful change; the Endowment maintains a substantial ownership position.

Key Dates

Recommendation

The reported trades are small and routine in nature for a 10% owner, with no new information on business performance, outlook, or strategy. No change to investment thesis based on this filing alone.

Keywords

Eli Lilly, LLY, Lilly Endowment, Form 4, insider sale, beneficial ownership, 10% owner, open-market transaction, common stock, SEC